AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...

AstraZeneca receives CDSCO approval for Durvalumab, a new treatment for muscle-invasive bladder cancer in India. This marks a ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

Real-time updates on ASTRAZENECA PHARMA share price. Check out the detailed analysis of the company in this live blog.

Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of ...